We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk

By LabMedica International staff writers
Posted on 16 Nov 2026

Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. More...

Blood-based liquid biopsies offer a potential complementary approach, although early-stage cancers often release limited genetic material, making accurate detection difficult. Assessing the risk of recurrence after treatment presents an additional challenge, highlighting the need for more sensitive blood-based diagnostic tools.

Researchers at the Hebrew University of Jerusalem, in collaboration with the Weizmann Institute of Science, Kaplan Medical Center, and Sheba Medical Center, developed a blood test that detects epigenetic signatures associated with breast cancer. The method analyzes circulating nucleosomes, fragments of DNA wrapped around proteins that are released into the bloodstream when cells die. Using single-molecule microscopy and fluorescent labeling, the technology measures multiple epigenetic markers across millions of nucleosomes to identify cancer-associated patterns.

The study initially examined epigenetic signatures in breast tumors from 12 women scheduled for surgical removal. Researchers then applied the blood-based approach to samples from 77 breast cancer patients followed for at least five years at Mayo Clinic in Florida, alongside 30 healthy women. Artificial intelligence models trained on these measurements distinguished women with early-stage breast cancer from healthy controls with 95% accuracy, including cases in which tumors were confined to the breast and measured no more than 2 centimeters.

The analysis was subsequently expanded to 188 patient blood samples with support from Sheba and Kaplan medical centers. The test demonstrated similar performance across different breast cancer types and breast densities. Researchers also identified a rare population of highly aggressive, invasive tumor cells with a distinct epigenetic signature, including in cancers not otherwise classified as particularly aggressive.

The presence of this aggressive-cell signature in blood was associated with an increased risk of recurrence. By combining it with additional epigenetic markers, the test distinguished patients who experienced cancer recurrence during follow-up from those who remained recurrence-free with 81% accuracy. Published in Nature, the findings suggest that blood-based epigenetic profiling could support earlier breast cancer detection and more personalized recurrence risk assessment.

“Breast cancer screening saves lives. Regular mammograms reduce the risk of dying from the disease by 22%, but the denser the breast tissue, the easier it is for a tumor to 'hide' in the image. Our blood test showed strong diagnostic performance regardless of breast density. It performed just as well across different types of breast cancer, and also when we expanded the number of patient blood samples to 188 with the help of Sheba and Kaplan Medical Centers,” said Efrat Shema of the Weizmann Institute of Science.

“When we looked for their epigenetic signature in blood samples, we found that the more prevalent it was, the greater the risk that the disease would come back,” said Guy Ron of the Hebrew University of Jerusalem.

Related Links
Hebrew University of Jerusalem
Weizmann Institute of Science


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.